SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Senti Biosciences Holdings, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.23+0.00 (+0.84%)

Close on Oct 19, 2026

Market cap: $7.06M
P/E (TTM): –
Dividend yield: –

Senti Biosciences Holdings, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	0.02	0	2.56	4.29	2.76
Research & Development	38	34	32	28	22
General & Administrative	26	26	37	38	21
Operating Expenses	69	61	95	66	43
Operating Income	-69	-61	-93	-62	-40
Other Non-Operating Income	7.34	8.25	9.32	12	-15
Asset Impairment Charges	5.05	0.31	26	0	0.02
Gain (Loss) on Sale of Assets	–	0	22	0	-0.02
Income Tax Expense	0	0	–	–	–
Income from Continuing Operations	-61	-53	-83	-50	–
Income from Discontinued Operations	–	0	12	-8.55	–
Net Income	-61	-53	-71	-58	-55
Net Income to Common	-61	-55	-71	–	–
EPS (Basic)(per share)	-2.73	-12.03	-16.01	-22.30	-190.00
EPS (Diluted)(per share)	-2.73	-12.03	-16.01	-22.30	-190.00
Shares Outstanding (Basic, Weighted)(shares)	22	4.60	4.44	2.61	0.29
Shares Outstanding (Diluted, Weighted)(shares)	22	4.60	4.44	2.61	0.29

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -248586.4%
Net margin: -225290.9%
Return on equity, FY2025: -393.4%

Financial strength

Current ratio: 0.83
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 41.0%

Valuation

P/E ratio: –
Price to sales: 321.07
Price to book: –
Dividend yield: –